MA29403B1 - Forme cristalline d'un compose quinolinone-carboxamide - Google Patents

Forme cristalline d'un compose quinolinone-carboxamide

Info

Publication number
MA29403B1
MA29403B1 MA30317A MA30317A MA29403B1 MA 29403 B1 MA29403 B1 MA 29403B1 MA 30317 A MA30317 A MA 30317A MA 30317 A MA30317 A MA 30317A MA 29403 B1 MA29403 B1 MA 29403B1
Authority
MA
Morocco
Prior art keywords
forms
quinolinone
crystalline form
crystalline salt
carboxamide compound
Prior art date
Application number
MA30317A
Other languages
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA29403B1 publication Critical patent/MA29403B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UN CHLORHYDRATE CRISTALLIN D'ACIDE 1-ISOPROPYL-2-OXO-1,2-DIHYDROQUINOLINE-3-CARBOXYLIQUE {(1S,3R,5R)-8-[(R)-2-HYDROXY-3-(MÉTHANESULFONYL-MÉTHYL-AMINO)PROPYL] -8-AZABICYCLO[3.2.1]OCT-3-YL}AMIDE OU UN SOLVATE DE CELUI-CI. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES FORMES DE SEL CRISTALLIN, DES MÉTHODES D'UTILISATION DE CES FORMES DE SEL CRISTALLIN POUR TRAITER DES MALADIES ASSOCIÉES À L'ACTIVITÉ DE RÉCEPTEUR DE 5 HT4 ET DES PROCÉDÉS UTILES POUR LA PRÉPARATION DE CES FORMES DE SEL CRISTALLIN.
MA30317A 2005-04-06 2007-10-25 Forme cristalline d'un compose quinolinone-carboxamide MA29403B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
MA29403B1 true MA29403B1 (fr) 2008-04-01

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30317A MA29403B1 (fr) 2005-04-06 2007-10-25 Forme cristalline d'un compose quinolinone-carboxamide

Country Status (29)

Country Link
US (4) US7728004B2 (fr)
EP (1) EP1874766B1 (fr)
JP (2) JP5230407B2 (fr)
KR (1) KR101322873B1 (fr)
CN (1) CN101151264B (fr)
AR (2) AR053208A1 (fr)
AT (1) ATE479682T1 (fr)
AU (1) AU2006232129B2 (fr)
BR (1) BRPI0610657A2 (fr)
CA (1) CA2603654C (fr)
CY (1) CY1111275T1 (fr)
DE (1) DE602006016586D1 (fr)
DK (1) DK1874766T3 (fr)
EA (1) EA012115B1 (fr)
ES (1) ES2350495T3 (fr)
HR (1) HRP20100629T1 (fr)
IL (1) IL186023A (fr)
MA (1) MA29403B1 (fr)
MX (1) MX2007012438A (fr)
MY (1) MY151075A (fr)
NO (1) NO339699B1 (fr)
NZ (1) NZ561900A (fr)
PE (1) PE20061310A1 (fr)
PL (1) PL1874766T3 (fr)
PT (1) PT1874766E (fr)
SI (1) SI1874766T1 (fr)
TW (1) TWI377206B (fr)
WO (1) WO2006108127A2 (fr)
ZA (1) ZA200708071B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (fr) 2004-11-05 2009-05-20 Theravance, Inc. Composes de quinolinone-carboxamide
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1945632B1 (fr) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Modulateurs hétérocycliques de transporteurs à cassette liant l' atp
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
SI2225230T1 (sl) * 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2758321A1 (fr) 2009-04-13 2010-10-21 Theravance, Inc. Composes agonistes du recepteur 5-ht4 pour le traitement des troubles cognitifs
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (fr) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-méthylpyridin-2-yl) benzoïque
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
BR112020000482A2 (pt) 2017-07-31 2020-07-21 Theravance Biopharma R&D Ip, Llc métodos de tratamento de sintomas de gastroparesia usando velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
EP4590303A1 (fr) * 2022-09-20 2025-07-30 Alfasigma S.p.A. Velusetrag destiné à être utilisé dans le traitement de la pseudo-obstruction intestinale chronique (poic)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
EP0670319A4 (fr) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd Compose heterocyclique.
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (fr) * 2004-11-05 2009-05-20 Theravance, Inc. Composes de quinolinone-carboxamide
WO2006088988A1 (fr) 2005-02-17 2006-08-24 Theravance, Inc. Forme cristalline d'un compose d'indazole/carboxamide
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
KR101322873B1 (ko) 2013-10-30
EA200702161A1 (ru) 2008-04-28
CN101151264A (zh) 2008-03-26
US7728004B2 (en) 2010-06-01
EP1874766A2 (fr) 2008-01-09
DE602006016586D1 (de) 2010-10-14
WO2006108127A2 (fr) 2006-10-12
HK1110866A1 (en) 2008-07-25
TW200643020A (en) 2006-12-16
MY151075A (en) 2014-03-31
US9126994B2 (en) 2015-09-08
US20160095849A1 (en) 2016-04-07
PT1874766E (pt) 2010-11-30
ATE479682T1 (de) 2010-09-15
EA012115B1 (ru) 2009-08-28
KR20070116988A (ko) 2007-12-11
US20060229332A1 (en) 2006-10-12
DK1874766T3 (da) 2010-12-06
EP1874766B1 (fr) 2010-09-01
TWI377206B (en) 2012-11-21
NO20075574L (no) 2007-11-02
JP5230407B2 (ja) 2013-07-10
PL1874766T3 (pl) 2011-02-28
JP2008535848A (ja) 2008-09-04
AR053208A1 (es) 2007-04-25
NZ561900A (en) 2010-12-24
CN101151264B (zh) 2011-07-06
PE20061310A1 (es) 2007-01-23
WO2006108127A3 (fr) 2007-01-04
AU2006232129A1 (en) 2006-10-12
AU2006232129B2 (en) 2012-07-12
ZA200708071B (en) 2008-10-29
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
SI1874766T1 (sl) 2010-12-31
MX2007012438A (es) 2007-12-05
IL186023A0 (en) 2008-01-20
US20140256769A1 (en) 2014-09-11
BRPI0610657A2 (pt) 2010-07-13
ES2350495T3 (es) 2011-01-24
CY1111275T1 (el) 2015-08-05
AR110019A2 (es) 2019-02-13
CA2603654A1 (fr) 2006-10-12
JP2012153725A (ja) 2012-08-16
HRP20100629T1 (hr) 2010-12-31
US20100197728A1 (en) 2010-08-05
NO339699B1 (no) 2017-01-23
IL186023A (en) 2011-09-27
CA2603654C (fr) 2014-05-27

Similar Documents

Publication Publication Date Title
MA29403B1 (fr) Forme cristalline d&#39;un compose quinolinone-carboxamide
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
BR0314631A (pt) Derivados de pirrolidona como inibidores de maob
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d&#39;utilisation associés
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu&#39;agents therapeutiques
CA2534798A1 (fr) Utilisation de derives du thiazole comme modulateurs des recepteurs cannabinoides
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
RU2012140182A (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
MA27779A1 (fr) FORME CRISTALLINE D&#39;AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
MA29909B1 (fr) Derives de pyridazine
EP2120878A4 (fr) Forme pharmaceutique contenant deux ou davantage de principes actifs pharmaceutiques sous des formes physiques différentes
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
FR2850576B1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
NO20041059L (no) Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens
EP2945637B1 (fr) Utilisation d&#39;agonistes du recepteur nicotinique de l&#39; acetylcholine alpha 7
WO2007066115A3 (fr) Agents d&#39;imagerie innovants pour la fibrose
EP2664620A3 (fr) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acétamide, modulateur double de l&#39;activité du récepteur de chimiokine, forme cristalline et procédés
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu&#39;antagonistes des recepteurs de crth2
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
NO20090190L (no) Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
CL2008003358A1 (es) Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.
WO2007066119A3 (fr) Agents d&#39;imagerie innovants pour la fibrose
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav